Saturday 17 October 2026
Export SPRY’s income statement to Excel — free account
ARS Pharmaceuticals, Inc.
SPRY Healthcare Biotechnology
ARS Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $84.3 million, down 5.46% from fiscal 2024. In the quarter to June 2026, revenue grew 114.2%, EPS fell 37.0%, free cash flow fell 53.7% and total debt rose 138.5%, each against the same quarter a year earlier.
4.02
0.05
−1.23%
Follow SPRY
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
1 | 5 | 2 | — | — | — | — | — | — |
P/E ratio |
0.00 | 131.88 | 0.00 | 0.00 | 0.00 | — | — | — | — |
P/S ratio |
13.63 | 11.47 | 1,302.21 | 223.54 | 0.00 | — | — | — | — |
Altman Z-Score |
1.32 | 7.30 | 128.38 | 24.29 | 6.03 | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
(1.13) | 7.46 | 102.46 | 38.12 | 4.06 | — | — | — | — |
P/FCF ratio |
0.00 | 78.76 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Beneish M-Score |
(0.44) | — | — | 3,877.59 | — | — | — | — | — |
P/Operating CF |
(26.41) | 24.35 | (30.53) | (16.41) | 6.89 | — | — | — | — |
P/B ratio |
10.05 | 3.98 | 2.30 | 1.23 | 0.00 | — | — | — | — |
Price to Tangible BV |
11.51 | 4.10 | 2.30 | 1.23 | 0.00 | — | — | — | — |
EV/Sales |
12.72 | 8.73 | 743.94 | 44.26 | 0.00 | — | — | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
EV/Operating CF |
(6.28) | 57.47 | (5.12) | (1.66) | (7.84) | — | — | — | — |
EV/FCF |
(5.75) | 59.96 | (5.11) | (1.65) | (7.81) | — | — | — | — |
Quick Ratio |
6.91 | 13.75 | 95.51 | 50.59 | 7.34 | 40.26 | 0.56 | 3.92 | — |
Current Ratio |
7.28 | 14.26 | 96.92 | 51.01 | 7.42 | 40.69 | 0.59 | 4.04 | — |
Net Debt/EBITDA |
0.42 | 23.85 | 3.07 | 7.79 | 2.87 | 11.89 | 0.22 | 0.74 | — |
Debt/Assets |
51.43% | 19.76% | 0.00% | 0.09% | 8.02% | 0.80% | 30.97% | 28.08% | 0.00% |
Debt/Equity |
1.47 | 0.27 | 0.00 | 0.00 | 0.11 | 0.01 | (0.86) | 0.43 | — |
Asset Turnover |
0.25 | 0.31 | 0.00 | 0.01 | 0.02 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
1.00 | 1.66 | 1.09 | 1.16 | 0.87 | 0.95 | 0.79 | 0.96 | — |
Capex/Depreciation |
1.97 | 1.12 | 0.03 | (0.62) | (0.26) | (1.37) | (0.16) | 0.00 | — |
Interest Coverage |
— | — | — | — | — | — | — | (852.09) | — |
| (92.38%) | 3.35% | (21.59%) | (28.71%) | (11.51%) | (20.33%) | 51.13% | 37.50% | — | |
| (50.50%) | 2.80% | (21.13%) | (20.23%) | (8.87%) | (16.05%) | (110.97%) | (127.63%) | — | |
ROIC |
(296.82%) | (15.85%) | (1,758.33%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
(69.05%) | 2.62% | (23.65%) | (12.72%) | (38.47%) | (8.61%) | 394.06% | (81.19%) | — |
Average Days of Receivables |
109.78 | 33.47 | 0.00 | 279.85 | 0.07 | — | — | — | — |
Research and Development Expense of Revenue |
15.64% | 21.96% | 67,553.33% | 1,396.35% | 368.20% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
273.05% | 80.40% | 157,613.33% | 1,402.43% | 85.13% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.04 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
26.22% | 16.30% | 30,783.33% | 444.00% | 51.38% | 0.00% | 0.00% | — | — |
Graham Net Nets |
0.06 | 0.23 | 0.43 | 0.80 | 0.23 | — | — | — | — |
Graham Number |
0.00 | 2.18 | 0.00 | 0.00 | 4.13 | — | — | — | — |
Earnings Yield |
(15.02%) | 0.76% | (10.22%) | (10.31%) | (10.49%) | — | — | — | — |
Free Cash Flow Yield |
(16.25%) | 1.27% | (11.19%) | (11.97%) | (9.16%) | — | — | — | — |
Revenue per Share |
0.86 | 0.92 | 0.00 | 0.03 | 0.19 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(1.73) | 0.14 | (0.62) | (1.00) | (0.61) | (10.73) | (28.59) | (0.51) | — |
Capex per Share |
(0.08) | (0.08) | 0.00 | 0.00 | 0.00 | (0.32) | (0.15) | 0.00 | — |
Free Cash Flow per Share |
(1.82) | 0.06 | (0.62) | (1.01) | (0.61) | (11.04) | (28.74) | (0.51) | — |
Cash per Share |
2.49 | 3.24 | 2.40 | 6.87 | 2.08 | 132.96 | 15.09 | 0.61 | — |
Shareholders Equity per Share |
1.16 | 2.65 | 2.42 | 6.83 | 1.55 | 131.69 | (8.48) | 0.55 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
1.16 | 2.65 | 2.42 | 6.83 | 1.55 | 131.69 | (8.48) | 0.55 | — |
Free Cash Flow |
(179.06) | 5.49 | (59.44) | (40.28) | (17.62) | (32.11) | (18.99) | (16.87) | — |
Working Capital |
245.75 | 310.86 | 229.34 | 272.26 | 52.54 | 381.06 | (7.40) | 15.63 | — |
Capital Expenditures |
(8.20) | (8.06) | (0.17) | (0.20) | (0.05) | (0.92) | (0.10) | (0.45) | — |
Net Current Asset Value |
71.50 | 239.94 | 229.30 | 269.15 | 44.05 | 378.73 | (10.72) | 11.43 | — |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Capex to Sales |
0.10 | 0.09 | 5.83 | 0.15 | 0.01 | 0.00 | 0.00 | — | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
(1.69) | (6.73) | (11.80) | 0.97 | 2.96 | 0.41 | 0.47 | 0.24 | — |
Cash ROIC |
(33.93%) | 0.86% | (12.95%) | (7.36%) | (16.05%) | (4.16%) | (206.03%) | (36.61%) | — |
Accounts Receivable Turnover |
5.03 | 19.41 | 0.00 | 2.61 | 0.00 | — | — | — | — |
Accounts Payable Turnover |
0.67 | 0.08 | 0.00 | 0.08 | 0.07 | 0.56 | 0.72 | 0.66 | — |
Inventory Turnover |
3.01 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
678.21 | 8,533.23 | 0.00 | 5,642.05 | 5,324.20 | 551.34 | 830.58 | 199.21 | — |
Days of Inventory on Hand |
149.57 | 1,947.16 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Receivables |
16.76 | 4.59 | — | 0.51 | — | — | — | — | — |
Average Payables |
30.39 | 12.50 | 3.54 | 4.02 | 2.85 | 3.05 | 2.15 | 2.15 | — |
Average Inventory |
6.79 | — | — | — | — | — | — | — | — |
Average Assets |
339.40 | 292.17 | 257.31 | 171.44 | 228.13 | 205.23 | 21.60 | 13.77 | — |
Average Common Equity |
185.53 | 243.78 | 251.82 | 120.81 | 175.80 | 162.05 | (46.88) | (46.88) | — |
Columns are period end dates